

CLAIMS

1. A stent for in vivo placement, said stent comprising being formed in a substantially tubular shape and expandable
5 in the outward radial direction of the substantially tubular shape, containing a material nondegradable in vivo, and a poly (lactide-co-glycolide) on at least a portion of the surface thereof.
- 10 2. The stent according to claim 1, wherein the poly (lactide-co-glycolide) is on either the outer surface or the inner surface of the stent.
- 15 3. The stent according to claim 1, wherein the poly (lactide-co-glycolide) is over substantially the entire surface including the outer surface, the inner surface, and the side surfaces of the stent.
- 20 4. The stent according to any one of claims 1 to 3, wherein the weight-average molecular weight of the poly (lactide-co-glycolide) is 5,000 to 130,000.
- 25 5. The stent according to any one of claims 1 to 4, wherein the molar ratios of lactic acid and glycolic acid which constitute the poly (lactide-co-glycolide) are 50 mol% to 85 mol% and 15 mol% to 50 mol%, respectively.
6. The stent according to any one of claims 1 to 5, wherein

the weight of the poly (lactide-co-glycolide) being on the stent is 3 $\mu\text{g}/\text{mm}$ to 80 $\mu\text{g}/\text{mm}$ per unit length in the axial direction of the stent.

5 7. The stent according to claim 6, wherein the weight of the poly (lactide-co-glycolide) being on the stent is 7 $\mu\text{g}/\text{mm}$ to 65 $\mu\text{g}/\text{mm}$ per unit length in the axial direction of the stent.

10 8. A stent for in vivo placement comprising being formed in a substantially tubular shape and expandable in the outward radial direction of the substantially tubular shape, containing a material nondegradable in vivo, and a poly (lactide-co-glycolide) and an immunosuppressive agent on at
15 least a portion of the surface thereof.

9. The stent according to claim 8, wherein the poly (lactide-co-glycolide) and the immunosuppressive agent are on either the outer surface or the inner surface of the stent.

20

10. The stent according to claim 8, wherein the stent has the poly (lactide-co-glycolide) and the immunosuppressive agent are over substantially the entire surface including the outer surface, the inner surface, and the side surfaces of
25 the stent.

11. The stent according to any one of claims 8 to 10, wherein the weight-average molecular weight of the poly

(lactide-co-glycolide) is 5,000 to 130,000.

12. The stent according to any one of claims 8 to 11,
wherein the molar ratios of lactic acid and glycolic acid
5 which constitute the poly (lactide-co-glycolide) are 50 mol%
to 85 mol% and 15 mol% to 50 mol%, respectively.

13. The stent according to any one of claims 8 to 12,
wherein the immunosuppressive agent is tacrolimus (FK-506),
10 cyclosporine, sirolimus (rapamycin), azathioprine,
mycophenolate mofetil, or an analogue thereof.

14. The stent according to claim 13, wherein the
immunosuppressive agent is tacrolimus (FK-506).
15

15. The stent according to any one of claims 8 to 14,
wherein the total weight of the poly (lactide-co-glycolide)
and the immunosuppressive agent contained in the stent is 3
 $\mu\text{g/mm}$ to 80 $\mu\text{g/mm}$ per unit length in the axial direction of
20 the stent.

16. The stent according to claim 15, wherein the total
weight of the poly (lactide-co-glycolide) and the
immunosuppressive agent being on the stent is 7 $\mu\text{g/mm}$ to 65
25 $\mu\text{g/mm}$ per unit length in the axial direction of the stent.

17. The stent according to any one of claims 8 to 16,
wherein the weight ratios of the poly (lactide-co-glycolide)

and the immunosuppressive agent are 30% by weight to 80% by weight and 20% by weight to 70% by weight, respectively.

18. The stent according to claim 17, wherein the weight
5 ratios of the poly (lactide-co-glycolide) and the immunosuppressive agent are 40% by weight to 70% by weight and 30% by weight to 60% by weight, respectively.

19. The stent according to any one of claims 8 to 18,
10 comprising an inner layer provided on a the surface of the stent, said inner layer containing the poly (lactide-co-glycolide) and the immunosuppressive agent, and an outer layer provided on the outer surface of the inner layer, said outer layer containing only the poly (lactide-co-glycolide).

15